NK/T cell lymphoma (NKTCL) is a challenging lymphoma variant known for its aggressive nature and less-than-favorable prognosis. A ray of hope has emerged in the form of Chimeric Antigen Receptor T (CAR-T) cell treatment, which is rapidly gaining traction as a potent method to counter blood-related cancers.
This research focused on the creation and assessment of four unique CAR-T cell variants: CD38-CAR, LMP1-CAR, and two versions of CD38-LMP1 tandem CAR. Their effectiveness against NKTCL was thoroughly tested in controlled environments and live models. Additionally, advanced flow cytometry techniques were employed to measure the activation markers in T cells and assess the cytokines released by the CAR-T cells.
All four CAR-T variants showcased a strong capability to counter and destroy malignant NKTCL cells. Their activation and subsequent release of pro-inflammatory cytokines were found to be directly related to the presence of target cells. More promisingly, when introduced to a mouse model with NKTCL grafts, the CAR-T cells consistently displayed impressive antitumor activities.
The comprehensive study emphasizes the considerable potential of CD38 and LMP1 CAR-T cell variants in tackling NKTCL. Both in controlled settings and live models, the CAR-T cells have proven their mettle by effectively combating NKTCL cells, underscoring their potential as a future therapeutic option.